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Purpose: The incidence of adenocarcinoma on a subsequent biopsy following a diagnosis 
of atypical small acinar proliferation (ASAP) ranges from 34% to 60%. We reexamined 
radical prostatectomy (RP) specimens of patients diagnosed as having synchronous 
ASAP with prostate cancer (PCa) to evaluate pathological entities and the clinical sig-
nificance of ASAP.
Materials and Methods: From January 2007 to December 2008, a total of 118 patients 
who had been diagnosed with adenocarcinoma on prostate needle biopsy underwent 
RP. Forty-six of the 118 patients (39%) were diagnosed as having synchronous ASAP 
with PCa on the prostate needle biopsy. Using whole-mount sections and prostate map-
ping, we evaluated the RP specimens that were close sections to the ASAP on prostate 
needle biopsy. All tissues were examined by immunohistochemistry with high molec-
ular weight cytokeratin (34βE12), p63, and AMACR/P504S added to initial H&E stains 
by one pathologist.
Results: Thirty-six of the 46 patients (78%) were diagnosed as having adenocarcinoma 
at sites of ASAP on the initial prostate needle biopsies. The Gleason score was 5 to 6 
in 22 patients (61%), 7 in 3 (8%), and unknown due to multifocal and microfocal lesions 
in 11 (31%). The tumor volume of 14 of the 36 patients (39%) was 0.5 cc or less and was 
unknown due to multifocal and microfocal lesions in 8 (22%).
Conclusions: Most ASAP on initial prostate needle biopsy was a true pathological en-
tity, in other words, prostatic adenocarcinoma. Aggressive approaches including more 
extended repeat biopsy with additional biopsy of the site of the ASAP are needed to diag-
nose PCa in patients with ASAP.
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The term ‘atypical small acinar proliferation (ASAP)’ was 
introduced by Bostwick et al to indicate suspicious glands 
with insufficient cytological or architectural atypia for the 
diagnosis of a definitive adenocarcinoma in prostate biop-
sies [1]. The incidence of ASAP in prostate biopsies was 
0.4% to 23.4% in 12 consecutive studies [2]. The clinical sig-
nificance of ASAP is its predictive value for prostate cancer 
(PCa) in a repeat biopsy, which ranged from 34% to 60% in 
similar studies [3,4]. On this account, current recom-
mendations for patients with ASAP in their initial biopsy 
are subsequent biopsy within 3 to 6 months irrespective of 
follow-up prostate-specific antigen (PSA) values [5].
　Immunohistochemical stains with benign prostate basal 
cell markers such as high molecular weight cytokeratin 
(34βE12) or p63 and markers of cancer such as alpha-meth-
ylacyl CoA racemase (AMACR/P504S) have been used for 
the differential diagnosis of ASAP and adenocarcinoma, al-
though neither stain confirms a definitive diagnosis for Korean J Urol 2010;51:398-402
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PSA: prostate-specific antigen, %fPSA: % free PSA, PSAD: PSA density, Cancer: patients were revealed as PCa at the sites diagnosed
as ASAP on initial prostate needle biopsy, No cancer: patients were not revealed as PCa at the sites diagnosed as ASAP on initial prostate
needle biopsy, 
a: Student’s t-test
PCa [6-8]. In addition, contemporary prostate biopsy proto-
cols have increased the number of cores from sextant biopsy 
to extended biopsy [9]. A recent report suggested that these 
advances have reduced the predictive value of ASAP for 
subsequent cancer to 37% [10]. By contrast, a report of im-
mediate prostatectomies after isolated ASAP was diag-
nosed described a 100% predictive value of ASAP [11]. 
There are many differences in the pathological entities and 
clinical significance of ASAP between studies.
　We reviewed radical prostatectomy (RP) specimens in 
patients with synchronous ASAP with PCa on prostate 
needle biopsy to evaluate the pathological entities and, by 
extension, the clinical significance of ASAP.
MATERIALS AND METHODS
From January 2007 to December 2008, we conducted sys-
tematic transrectal ultrasound (TRUS)-guided prostate 
needle biopsies at our institution because of increased se-
rum PSA values or abnormality on a digital rectal examina-
tion (DRE). Prostate biopsies were acquired under TRUS 
(IU-22; PHILIPS, USA) guidance by using a biopsy gun 
(ACECUT; TSK Laboratory, Japan) with an 18 gauge nee-
dle by one radiologist. We performed 6-core biopsies [12] 
in patients with a TRUS volume of less than 30 cc and 
12-core biopsies [13] in patients with a TRUS volume of 30 
cc or more. All specimens were stained with H&E to eval-
uate features considered specific for carcinoma. In addi-
tion, immunohistochemical stains such as 34βE12, p63, 
and AMACR/P504S were used for the differential diag-
nosis of ASAP and carcinoma. All tissues were evaluated 
by one pathologist.
　A total of 118 patients underwent RP because they were 
diagnosed with PCa on the prostate needle biopsy at our 
institution. Forty-six of the 118 patients (39%) were diag-
nosed as having synchronous ASAP with PCa on the pros-
tate needle biopsy. In those 46 patients, the mean age was 
69.63 years (range, 57-78 years), the mean PSA level before 
the prostate biopsy was 8.17 ng/ml (range, 1.75-26.89 
ng/ml), and the mean prostate volume was 34.40 cc (range, 
19.10-95.40 cc). The RP pathology results (Table 1) showed 
that the patients had a mean Gleason score of 6.65 (range, 
5-9) and a mean pathological stage of pT2c-pT3a (range, 
pT2a-pT3c).
　All specimens acquired from RP were mapped by using 
complete sampling with whole-mount sections [14]. Using 
prostate mapping, we retrospectively evaluated the sites 
in the RP specimens that had been diagnosed as ASAP on 
prostate needle biopsy. All RP specimens were examined 
with the same H&E stain and immunohistochemical stains 
by one pathologist who had previously evaluated the pro-
state needle biopsies. For measurement of tumor volume, 
visual inspection and grid morphometric analysis were 
done (tumor volume=1.25 x mean percentage carcinoma x 
number of block).
　Student’s t-test was used to assess the clinical values. 
Statistical analysis was performed by using statistical soft-
ware (SPSS 10.1; SPSS Inc., USA), and a p-value of less 
than 0.05 was considered to indicate a statistically sig-
nificant difference.
RESULTS
Thirty-six of the 46 patients (78%) who underwent RP were 
shown to have adenocarcinoma at the sites diagnosed as 
ASAP on the initial prostate needle biopsy. The character-
istics of these 36 patients and those of the other 10 patients 
who were not diagnosed are shown in Table 2. Only patho-
logical stage was statistically significantly different be-
tween the groups (p＜0.005).
　Of the 36 patients, pathological stage was T2a in 4 pa-Korean J Urol 2010;51:398-402
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TABLE 3. Pathological stages and Gleason scores in the 36 patients
No. of patients 
(n=36)











5-6 (3), unknown (1)
5-6 (11), 7 (1), unknown (3)
5-6 (3), 7 (1), unknown (2)
5-6 (3), unknown (1)
5-6 (2), 7 (1), unknown (4)
FIG. 1. Pathological stages and Gleason scores in 36 patients.
tients, T2c in 15, T3a in 6, T3b in 4, and T3c in 7. Four of 
the 36 patients (11%) had lesions located at one lobe and 
19 of them (53%) were organ-confined disease.
　The Gleason score was 5 to 6 in 22 patients (61%), 7 in 
3 (8%), and unknown in 11 (31%). The patients with an un-
known Gleason score had cancerous features but a Gleason 
score could not be assigned because of multifocal and very 
small lesions. In particular, of the 25 patients who were as-
signed a Gleason score, 22 (88%) were diagnosed with a 
Gleason score of 6 or less. Table 3 and Fig. 1 summarize the 
pathological stages and Gleason scores in the 36 patients.
　Of the 36 patients, the mean tumor volume of 28 of the 
patients in whom we could assess tumor volume was 2.5 
cc, and 14 of the 28 patients (50%) had a tumor volume of 
0.5 cc or less. Eight of the 36 patients could not be evaluated 
because of multifocal lesions.
　The 10 patients not diagnosed as having PCa (at the site 
of the ASAP on the initial needle biopsy) had pT2a (9 pa-
tients), pT3a (1 patient), a Gleason score of 6 (7 patients), 
and a Gleason score of 7 (3 patients) in the RP pathology 
results.
DISCUSSION
PCa is diagnosed by prostate needle biopsy when patients 
have an elevated serum PSA level, an abnormality on the 
digital rectal examination, or a low echoic lesion on TRUS. 
Park et al reported that among 1,045 men who underwent 
TRUS-guided systematic needle biopsy, 104 underwent re-
peat prostate biopsies after a previous negative biopsy, and 
PCa was detected in 22 (21.2%) of the 104 patients [15]. A 
false-negative result on the initial biopsy or a delayed diag-
nosis can result because of the difficulty of diagnosing can-
cer from a prostate needle biopsy specimen. This difficulty 
is due to the fact that quantitative and qualitative changes 
are necessary for a pathological diagnosis of adeno-
carcinoma, the amount of prostatic tissue acquired by nee-
dle-core biopsy is limited, and a certain degree of sub-
jectivity is involved in the pathological diagnosis [11]. 
Therefore, ASAP has commonly been used to refer to an 
atypical focus suspicious but not diagnostic of malignancy 
[3]. The terminology of ASAP encompasses various lesions 
including benign lesions, small acinar proliferations mim-
icking PCa, and atypical glandular proliferations suspi-
cious for carcinoma, which cannot be accurately diagnosed 
for a various reasons such as insufficient amount of speci-
men or biopsy-induced mechanical distortion [16]. Despite 
the popular recognition of ASAP as a pathological diag-
nosis, criticism does exist. First, ASAP legitimizes patho-
logical uncertainty by reporting it like a diagnosis. Second, 
ASAP may have differences of opinion between indepen-
dent pathologists. Concordance rates of 84% and 78% be-
tween independent pathologists were described in pre-
vious studies [17]. Third, several large studies reported a 
subsequent biopsy rate of ＜70% after a diagnosis of ASAP 
on the first prostate biopsy [18-20]. Finally, delayed diag-
nosis can result because the term ASAP does not ad-
equately convey the seriousness of the biopsy result to ei-
ther the urologist or the patient [17]. Even though ASAP 
might be incomplete in terms of pathological diagnosis, its 
predictive values for PCa on repeat biopsy ranged from 34% 
to 60% in previous studies [3,4]. We identified PCa post-
operatively in 78% of ASAP identified in the initial prostate 
needle biopsy.
　Brausi et al reported that 25 of 71 patients with isolated 
ASAP underwent immediate RP and 23 of them underwent 
subsequent biopsy. All 25 patients (100%) who underwent 
RP had a final pathological diagnosis of adenocarcinoma 
and 9 of the 23 patients (39.1%) who underwent follow-up 
biopsies were diagnosed as having adenocarcinoma in 6 to 
12 months after the initial diagnosis of ASAP. Those au-
thors suggested RP as one of the treatment choices in young 
patients with isolated ASAP on prostate needle biopsy. In 
their study, 9 of the 25 patients (36%) had a tumor localized 
to a single lobe (pT2a) with a Gleason score of 2 to 6, and 
the cancer volume was less than 0.5 cc in 3 of these 9 
patients. Even though 4 (16%) patients had cancers with 
a Gleason score of 7 or more, the others had relatively 
low-grade cancer, which might indicate clinically insignif-
icant PCa [11].
　In another study, Flury et al reviewed whole-tissue sec-
tions of prostates removed at 65 cystoprostatectomies [21]. 
They reported that 2 of 10 ASAP foci were diagnosed as ad-
enocarcinoma with additional sectioning of the corre-
sponding tissue block. In addition, 6 of 10 ASAP foci had 
immunohistochemistry supporting a cancer diagnosis, but Korean J Urol 2010;51:398-402
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not enough material for such a diagnosis. Two foci that were 
diagnosed as PCa had a total volume of much less than 0.5 
cc and a Gleason score of 6, respectively. Those authors pro-
posed that ASAP represented clinically insignificant PCa 
or marginally sampled PCa and that aggressive diagnostic 
approaches to seek PCa were necessary whenever ASAP 
is seen on prostate needle biopsy [21]. If a carcinoma is mar-
ginally or imperfectly sampled, the microscopic focus 
might be very small and might contain only a small number 
of acini [3]. This is certainly a contributory factor to having 
much difficulty in evaluating specimens.
　Previous studies described the adenocarcinomas found 
on follow-up biopsy to be of various grades, 18% to 71% had 
Gleason scores of 5 or 6, and 29% to 82% were PCa with 
Gleason scores of 7 or more [17,22,23]. Ultimately, ASAP 
represented ‘a marginally sampled, tangentially sectioned 
or out-pouching adenocarcinoma’ [24].
　The Epstein criteria are currently one of the most widely 
used definitions for clinically insignificant PCa. These are 
composed of PSA density of 0.15 ng/ml
2 or less, Gleason 
score of 6 or less, fewer than three biopsies with PCa, and 
up to 50% of cancer involvement in any core. In another 
study, clinically insignificant cancer was defined as that 
with an RP tumor volume of less than 0.5 cc, a Gleason score 
of 6 or less, and organ-confined cancer [25]. van Oort et al 
reported that the biological behavior of small volume and 
insignificant PCa was significantly more favorable than 
that of a general group of patients undergoing RP [26]. For 
that reason, patients with such insignificant cancer may 
be appropriate candidates for active surveillance rather 
than initial radical therapies. But, the plain fact is that the 
Epstein criteria cannot predict clinically insignificant PCa 
accurately in some cases and may underestimate the true 
nature of PCa in 30.5% of Korean patients and 24% of 
European patients [27,28].
　In our study, 61% of the patients diagnosed as having 
PCa had low-grade cancer with a Gleason score of 5 or 6 and 
8% of them had intermediate-grade cancer with a Gleason 
score of 7. In 31% of our patients, the Gleason score could 
not be evaluated because of multifocal and very small 
lesions. Also, 39% of the patients diagnosed as having PCa 
had a tumor volume smaller than 0.5 cc. Together with the 
aforementioned studies, our data strongly suggest that 
ASAP represents clinically insignificant PCa or margin-
ally sampled PCa.
　Mechanical distortion from the needle biopsy can result 
in crush artifact of a few atypical glands and obscure cyto-
logic detail. Problems with fixation and processing can pre-
vent a definite diagnosis because of poor histological fea-
tures [3]. We suggest that alteration of cytological features 
could result from needle-core biopsy, especially in small- 
volume foci and that these were some of the reasons we did 
not find significant features in 10 patients even though the 
RP specimens contained sufficient tissue.
　Matsumoto et al found a 7.7% increase in cancer detec-
tion by use of an additional far lateral sextant biopsy in the 
peripheral zone, and the 12-core biopsy scheme yielded a 
7.7% to 13.8% increase in cancer detection in a Japanese 
series [29]. Furthermore, a recent study by Ploussard et al 
reported that the 21-core extended biopsy improved the di-
agnostic yield of 39.1% for ASAP compared with 12-core bi-
opsy and cancers were found at the same sample site (71%) 
and side (100%) by using subsequent 21-core biopsy of pa-
tients with an initial diagnosis of ASAP [30]. In another 
study, it was reported that sampling only the side or sex-
tant site with ASAP would have failed to detect cancer in 
39% of patients with cancer detected exclusively in other 
sites [22]. Therefore, our data and the aforementioned 
studies suggest that aggressive extended sampling will do 
better to include additional biopsy of the site of ASAP and 
saturation biopsy.
　Several limitations to our study exist. Because isolated 
ASAP is not a generally accepted indication of RP, we eval-
uated RP specimens with synchronous ASAP with ad-
enocarcinoma and could not evaluate RP specimens with 
isolated ASAP. Therefore, the diagnosis rates of adeno-
carcinoma were different between a previous study [11] 
and ours (100% vs. 78%). But there was no difference be-
tween the characteristics of cancer, such as low grade and 
small volume caner. In addition, only a limited number of 
patients (46) underwent RP due to synchronous ASAP with 
PCa. Also, because we did not routinely perform RP in 
high-risk patients, which was defined as clinical stage T3b 
or higher disease or PSA greater than 20 ng/ml or a Gleason 
score of 8 or greater, advanced PCa was excluded from the 
beginning of our study. The context results in no significant 
differences in Gleason pattern between PCa on reexamin-
ing whole tissue sections from the site of ASAP and PCa on 
needle prostate biopsy.
CONCLUSIONS
Although the pathological entities and clinical significance 
of ASAP on prostate biopsies have been investigated com-
prehensively, a few studies have reported associations be-
tween ASAP on prostate needle biopsy and adenocarcinoma 
in whole tissue sections of surgery. The results of our study 
show that ASAP is most often marginally sampled cancer 
or clinically insignificant PCa. Therefore, we suggest that 
aggressive diagnostic approaches like additional biopsy of 
the site of the ASAP or more extended biopsy be imple-
mented as soon as possible if ASAP is diagnosed by prostate 
needle biopsy.
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